Cellular senescence is considered a key biological program that can exert both protective and potentially pathogenic effects in tissues across the lifespan. If senescent cells persist, they are associated with chronic inflammation, disturbed tissue homeostasis and diverse disease phenotypes. In recent years, a clinically highly relevant field of research has emerged from this: Senotherapies – in particular senolytics (selective elimination of senescent cells) and senomorphics (modulation of senescence-associated signaling and secretion patterns) – are widely studied in preclinical models, while human evidence to date comes mainly from early, small studies or from indirect clinical data sets.
You May Also Like
- Focus on new therapeutic targets and senolytics
Cellular senescence
- Development of a quintuple agonist
New strategy in the fight against obesity and T2D
- From symptom to diagnosis
Oncocytoma
- Arterial elasticity, vascular ageing, endothelial function
Longevity and cardiovascular health 2025
- AI-supported risk stratification for chest pain in the emergency room
Performance of a fully automated ECG model
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Hormone balance and longevity
Ageing is not a substitution diagnosis
- Cardiovascular risk